Although this possibility can be expanded to the speculation that the serum nm23 protein level reflects the tumor burden, it was not correlated with the serum LDH level in NK-NHL, in which the serum nm23-H1 level increased with progression of the disease, but it was not correlated with the serum LDH level. Therefore, it is more likely that the serum nm23-H1 level reflects the tumor proliferation rate rather than tumor burden at least in NK-NHL. 
We previously investigated mdr1, mrp, gst-p, topo I, topo IIa, and topo IIb expression in AML patients by RT-PCR, but none of these drug resistance-related genes were associated with cellular nm23-H1 expression. However, it is of interest to examine the relation between the levels of previously reported drug resistance-related genes and the serum nm23-H1 level because there was a significant correlation between the therapeutic response and the serum nm23-H1 level. The nm23-H1 protein level was lower in CR patients than in non-CR patients, and the prognosis was poor with regard to both OS and PFS in patients with an nm23-H1 level equal to or greater than 80 ng/ml. Thus, we employed 80 ng/ml as a cut-off value and investigated the effect of serum nm23-H1 level on OS and PFS of patients who were separated into two groups according to their IPI values (L+L-I and H-I+H risk groups) (Figure 1 ). Although the number of cases in the H-I+H risk group was small, patients with nm23-H1 protein level equal to or greater than 80 ng/ml showed poor prognosis in both of the two groups. It is, therefore, considered that patients with a high nm23-H1 protein level may require more aggressive treatment than the CHOP regimen and radiation may be necessary. Multivariate analysis demonstrated that the nm23-H1 level was an independent prognostic factor for NK-NHL. Based on these findings, we propose that determination of the serum nm23-H1 protein level is important for planning the treatment strategy for individual patients with NK-NHL.
Recently, nm23 has been investigated as a molecular target for inhibition of metastasis in breast cancer and melanoma. Many chemotherapeutic agents have been screened using the nm23 expression level as an indicator of metastatic potential. 7 In hematological malignancies, it might be a novel approach to identify the compounds with preferential inhibitory activity against overexpressed nm23. On the other hand, inhibition of nm23 expression by using antisense oligonucleotide treatment or by using transfection with a plasmid vector expressing the human nm23 antisense mRNA has been tried. 8 In leukemia, as a preliminary, tried to inhibit nm23 gene expression by nm23 antisense S-oligonucleotide, leading to suppression of proliferation and promotion of differentiation (data not shown). Therefore, overexpression of the nm23 gene may be a new molecular target for leukemia treatment and, in NK-NHL, the development of a new treatment regimen that targets nm23 overexpression is expected. 
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TO THE EDITOR
Previous work demonstrated statistically significant association between arabinose-cytidine triphosphate (ara-CTP) accumulation by leukemic myeloblasts and probability of response to ara-C in dose X1 gm/m 2 . Fludarabine is a deoxyadenosine analogue (2-fluoro-ara-AMP, FAMP) arabinosylcytosine that is rapidly dephosphorylated in vivo to 2-fluoro-ara-A. Intracellularly, it is phosphorylated to 2-fluoro-ara-ATP(FATP) by deoxycytidine (dCyd) and other kinases. Fludarabine has been postulated to be synergistic with arabinosylcytosine (ara-C), as a result of its effects on dCydkinase [deoxycytidine], which increase intracellular ara-CTP accumulation. We have reported that fludarabine (30 mg/m 2 ) + ara-C (0.5 g/ m 2 /h for 2-6 h daily) administered once daily for 5 days was superior to high-dose ara-C (HDAC: 3 gm/m 2 over 2 h every 12 h for 2-6 days) in acute myelogenous leukemia (AML) in relapse after an initial complete remission (CR) duration 4 1 year. 1 Daily administration of fludarabine-ara-C does not result in sustained intracellular ara-CTP levels. Accordingly, we explored twice-daily administration, with each dose of fludarabine given at 50%, and each dose of ara-C at 25%, the previous dose, based on the assumption that, because of the nonlinear relation between plasma ara-C and intracellular ara-CTP levels, such reduction would result in less than a 50% decrease in cellular ara-CTP levels; subsequently, because of the possibility that ara-C is more effective as a continuous infusion, a regimen combining fludarabine with continuous infusion ara-C was investigated. We compared these regimens with each other and with liposomal daunorubicin + ara-C, the principal nonfludarabine-containing salvage regimen used during the years (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) in which these fludarabine-based regimens were being evaluated.
A total of 248 patients with relapsed AML were enrolled in four separate protocols between 1990 and 2000. Patient characteristics and details of the regimens are described in Table 1 .
Fischer's exact test and the Kruskal-Wallis test were used to test the relation between the categorical and the continuous variable, respectively. Log-rank tests were used to test the difference in survival times by protocols and patient characteristics. Logistic regression and the Cox Proportional Hazard Model were used to assess as to which factors were independently predictive of CR and survival, respectively. Methods used to fit the models and to test the assumptions underlying the simple Cox model (log-linearity and no time-varying effects) have been described. Analyses were carried out using SAS 8.0 and Splus 2000.
CR rates varied from 20 to 35%, with once-daily fludarabine + ara-C ('QD FA'), producing the highest rate and fludarabine + continuous infusion ara-C ('CI A/QD F'), the lowest rates ( Table 2 ). The differences in CR rates were not statistically significant. In contrast and as found previously, 2 cytogenetics, number or prior salvage regimens, performance status, and duration of first remission were each associated with the probability of achieving CR ( Table 2 ).
Given that patients treated on the four regimens differed with respect to the above-mentioned variables (Table 1) , we used logistic regression to assess the effect of these differences on the evaluation of the regimens. After accounting for these factors (age, cytogenetics, duration of first remission, and the number of prior salvage therapies), the specific salvage regimen was not predictive. (The same applies if the twice-daily fludarabine + ara-C regimen is considered as two regimens (o vs 4 15 doses).
Survival was shortest with CI A/QD F and equivalent with liposomal daunorubicin (LDA), QD FA and BID-FA (twice-daily fludarabine) (Figure 1 ). The variables predictive of survival were essentially those predictive of CR. After accounting for these variables, survival was again shortest with CI A/QD F, but equivalent with the other three regimens. The risk of death with FCA was 2.64-fold greater than that seen with LDA.
Fludarabine-containing regimens, eg. 'FLAG' (fludarabine with granulocyte colony-stimulating factor, GCSF) or 'FLAG' + idarubicin (IDA') have found wide application in AML, particularly in Europe. [3] [4] [5] In general, however, reports citing beneficial results with these regimens have not included a formal control group consisting of patients not given fludarabine. We recently addressed this issue in newly diagnosed AML, reporting that, after accounting for prognostic covariates, there was no evidence that FLAG or FLAG + IDA was superior to idarubicin + continuous-infusion ara-C at 1.5 gm/m 2 daily Â 3-4 days. 6 The possible exception was in patients with inv(16) or t(8;21). Our analysis extends these findings to patients in relapse. However, suffers from the same flaws as the above-referenced paper. Chief among these is that the regimens were investigated sequentially rather in the context of a randomized clinical trial.
A second weakness is that liposomal daunorubicin + ara-C is itself an investigational regimen. In particular, it is unclear how it compares to more standard anthracycline + ara-C regimens. Such regimens were used relatively infrequently here, leading us to select liposomal daunorubicin + ara-C as our control regimen. Of course, it is possible that liposomal daunorubicin + ara-C is superior to say, idarubicin + ara-C. Were this true, it follows that our fludarabinecontaining regimens might also be superior.
A third weakness is the lack of discussion of causes of failure. In particular, might our fludarabine-containing regimens be associated with different types of failure than was liposomal daunorubicin + ara-C? We have found it difficult to discern whether a given failure reflects 'supportive care failure' or 'resistant AML'. The exceptions are, on the one hand, deaths occurring within 2-4 weeks after the start of therapy accompanied by marrow hypoplasia or, rarely, regeneration of normal elements, and, on the other hand, regrowth of AML or failure to produce hypoplasia. The early death rate (o14 days) was highest with CI A/QD F, with the difference being statistically significant compared to the other three regimens ( Table 1 ). The reasons for this difference remain unclear. It could be argued that reduction of the doses of fludarabine and ara-C might have lowered the early death rate, improved the CR rate, and lengthened survival. This emphasizes that our conclusions apply only to fludarabine + ara-C administered as described in Table 1 . Nonetheless, these drugs are, in fact, generally administered as described in this table. Note that the doses of ara-C differ with each of the three fludarabine-containing regimens (QD FA 10 mg/m 2 ). This could have affected the treatment outcome although it has been suggested that once ara-C dose rates of 0.5 g/m 2 /h are used, dose increases have no effect in the formation of ara-CTP. 7, 8 A final weakness, common to many trials, is that the results represent only an average. It is certainly possible that there are patients for whom a fludarabine-containing regimen would be superior. In this context, it is perhaps regrettable that we did not systematically examine the relation between ara-CTP formation 'fludarabine's principal 'target'' and response. In fact, a relatively large number of circulating blasts (eg 4 3000/m1) is needed to assess the ex vivo pharmacokinetics of ara-C; only 29% of 722 patients in first relapse, during the period covered by this report, had such a circulating blast count. This is a difficult issue in general, with some finding it preferable to treat relatively large numbers of patients on a given trial, even after it is clear that the average patient will not be benefited, so as to permit detection of patients most likely to respond. Others, including ourselves, have difficulty with this view.
With due consideration to these issues, we hope that our analysis leads to caution in accepting the value of the fludarabine-containing regimens described here in relapsed AML. While awaiting the results of the current Medical Research Council trial randomly assigning such patients to FLAG + IDA or a comparable regimen without fludarabine, it might be useful to focus on development of other treatments for such patients. 
The translocation, t(12;21)(p13;q22), is the most common chromosomal rearrangement in children with B-cell precursor acute lymphoblastic leukemia (ALL), occurring in approximately 25% of patients. 1, 2 It is invisible by G-banded chromosomal analysis and was discovered fortuitously by fluorescence in situ hybridization (FISH) using whole-chromosome painting probes in 1994 3 . The translocation fuses the 5 0 part of the ETV6 gene on the short arm of chromosome 12 (12p) with most of the AML1 gene on the long arm of chromosome 21 (21q), to produce the chimeric fusion transcript ETV6/AML1 on the derived chromosome 21 4 . Thus, FISH with probes specific for these regions or reverse transcriptase polymerase chain reaction (RT-PCR) with appropriate primers can be used in the detection of t(12;21). From detailed cytogenetic and FISH studies, a small number of variant and complex chromosomal rearrangements have been reported that involve chromosomes 12 and 21 in the production of the ETV6/AML1 fusion gene. 5, 6 This is the first report of the ETV6/AML1 fusion produced by a visible insertion of most of 12p into chromosome 21.
A 5-year-old boy presented with hepatomegaly, a white blood cell count of 28 Â 10 9 /l and 63% blasts on the blood film. Bone marrow examination showed increased cellularity with 96% lymphoblasts of L1 morphology. The blast cells were PAS positive, Sudan black and acid phosphate negative. The immunophenotype showed the leukemic cell population to be TdT, CD10 and CD19 positive, consistent with a diagnosis of common ALL. The patient was entered into the UK Medical Research Council ALL treatment trial, UKALLXI, for children aged 1-14 years. He has remained in continuous complete remission for 8 years.
Metaphases from the diagnostic bone marrow were examined by G-banded chromosomal analysis. Parallel multiplex-FISH (M-FISH) was performed with the 24-color chromosome painting kit (SpectraVysion, Vysis, UK) on the same cell suspension. Interphase nuclei were examined by FISH using the dual-color probe kit LSI TEL/AML1 ES (Vysis, UK). Other probes used for metaphase FISH analysis included directly labeled subtelomeric probes (Appligene Oncor, Qbiogene, UK) to chromosomes 1, 10, 12, 13 and 21, and cosmid exon-specific probes. There were nine cosmids covering the ETV6 gene, 179A6 (exon 1), 15A4 (exon/intron 1), 67C6 (intron 1), 50F4 (exon 2), 132B11 (intron 2), 242E1 (exon 3), 163E7 (exons 3-5), 54D5 (exons 5-8), 148B6 (exon 8), and two covering the AML1 gene, ICRF c103 CO664 (exons 1-5) and H11086 (exons 6 and 7). The probes for M-FISH, subtelomeres and specific gene exons were, when possible, sequentially applied to the same metaphases in order to obtain a complete cytogenetic picture.
For the molecular tests, mRNA was extracted from leukemic blood cells taken at diagnosis, reverse transcribed and screened for TEL/AML1 fusion sequences by RT-PCR as previously described.
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Interphase FISH revealed the ETV6/AML1 yellow fusion in 62% of cells together with one green signal indicating the retention of the ETV6 gene on the second copy of chromosome 12 and two red signals of similar size for AML1.
The complementary application of cytogenetics and sequential FISH revealed a highly complex karyotype: 48,XY,der(1)t(1;10)(q1; p1?1),+4,+10,der(10)t(10;13)(p1?1;q3?2)t(1;10)(q1;q1)t(1;12)(qter; pter)x2,der(12)del(12)(p11)t(1;12)(qter;p11),der(13)del(13)(q1 q32) t(10;13)(q1;q1),der(21)inv ins(21;12)(21pter421q21::12p134 12p13:: 21q22.1421q21: :12p11412p13::21q22.1421qter)/49, idem,+21. The italics indicate those abnormalities identified only by the subtelomeric probes. G-banding and M-FISH provided clear evidence of an insertion of a substantial amount of 12p into chromosome 21 and complex rearrangements involving the pericentromeric regions of chromosomes 1, 10 and 13. Five derived (der) chromosomes were defined in the karyotype (Figure 1 ). On three of these chromosomes, namely der(1)t(1;10), der(13)t(10;13) and der(21)ins(21;12), the signals of the 10p, 10q and 21q subtelomeric probes were observed in the expected locations ( Figure 1) . However, the der(10) and the der(12) had exchanged telomeres. The arm of the der(10) composed of 1q terminated with a 12p subtelomeric probe signal and the deleted 12p with the 1q subtelomeric probe signal (Figure 1 ). The subtelomeric probe 21q signal was seen on the der(21) confirming that 12p material had been inserted into 21q. Its presence on one or two normal copies of chromosome 21 verified that the second AML1 signal at interphase, represented an extra copy of chromosome 21.
Metaphase FISH with the exon-specific probes to AML1 showed the gene to be intact on the der(21) and on the one/two normal copies of chromosome 21. There was no reciprocal AML1 signal on the der(12), consistent with the findings from the 21q subtelomeric probe. The signals of the probes specific to the exons of ETV6 were all observed within the insertion of 12p into 21q. The origin of the gene from the der(12) was assumed, since there was a visible deletion and all the ETV6 exons were missing from it. Dual-color hybridization of the probes 179A6 and 148B6, specific for exons 1 and 8 of ETV6 showed a distinct separation of these two signals on the der(21). On a normal ETV6 gene, these probes when applied together usually appear closely apposed as a fusion signal. This dual-color hybridization also revealed that the orientation of the inserted material containing ETV6 appeared to be inverted in comparison with the position usually observed on an intact 12p. In this patient, the 5 0 end (exon 1) was in a centromeric rather than a telomeric position, while the 3 0 end (exon 8) was telomeric. At the same time, it was demonstrated that exon 8 was deleted from the second ETV6 allele on the homologous chromosome 12. Exons 1-7 were present on this chromosome, which appeared normal by cytogenetics and M-FISH.
Leukemic cells were positive for the ETV6/AML1 fusion transcript by RT-PCR. The amplicon was of the predicted size for the major ETV6/AML1 mRNA product (300 bp) and sequencing of the band confirmed that it was a (bona fide) ETV6 (exon 5)-AML1 exon 2 fusion mRNA. This result provided important verification that the usual ETV6/AML1 fusion event had occurred, since side by side positioning of AML1 and ETV6 on the der(21) would also have produced a colocalization of the AML1 and ETV6 signals 
